论文信息 - Post-alemtuzumab Graves’ disease remitting after switch to ocrelizumab - 字舞流文

Post-alemtuzumab Graves’ disease remitting after switch to ocrelizumab

V. Popescu | B. Decallonne | A. Beirinckx

[1] W. Wiersinga,et al. THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY. , 2021, European journal of endocrinology.

[2] F. Patti,et al. Rituximab for the treatment of multiple sclerosis: a review , 2021, Journal of Neurology.

[3] A. Belfiore,et al. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism , 2020, Frontiers in Endocrinology.

[4] M. Cole,et al. Adjuvant rituximab, a potential treatment for the young patient with Graves’ hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial , 2019, BMJ Open.